{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:52:45Z","timestamp":1790099565625,"version":"4.0.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jhepr.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T08:12:00Z","timestamp":1563264720000},"page":"227-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Anticoagulation in the cirrhotic patient"],"prefix":"10.1016","volume":"1","author":[{"given":"Laura","family":"Turco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"de Raucourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique-Charles","family":"Valla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-7022","authenticated-orcid":false,"given":"Erica","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2019.02.006_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2008.09.014","article-title":"The coagulation cascade in cirrhosis","volume":"13","author":"Monroe","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1532\/IJH97.03149","article-title":"Progress in the understanding of the protein C anticoagulant pathway","volume":"79","author":"Dahlb\u00e4ck","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1440-1746.1997.tb00351.x","article-title":"Natural anticoagulants and the liver","volume":"12","author":"Castelino","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0020","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/00007890-199404150-00011","article-title":"Predictive value of von Willebrand factor to ristocetin cofactor ratio and thrombin-antithrombin complex levels for hepatic vessel thrombosis and graft rejection after liver transplantation","volume":"57","author":"Jennings","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0030","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/hep.26372","article-title":"An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome","volume":"58","author":"Hugenholtz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.21231","article-title":"Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity","volume":"44","author":"Lisman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tmrv.2014.03.002","article-title":"Hemostasis in liver disease: implications of new concepts for perioperative management","volume":"28","author":"Weeder","year":"2014","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0045","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2017.12.027","article-title":"Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis","volume":"68","author":"Turco","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0038-1660523","article-title":"Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis","volume":"38","author":"Schepis","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.dld.2016.02.008","article-title":"Under the Auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: report of a consensus conference","volume":"48","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/hep.28148","article-title":"Thromboelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial","volume":"63","author":"De Pietri","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11894-017-0585-6","article-title":"Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy","volume":"19","author":"Zakeri","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0080","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/liv.13712","article-title":"Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis","volume":"38","author":"Hung","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0085","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0090","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cgh.2010.06.018","article-title":"Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease","volume":"8","author":"Giannini","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0095","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.22216","article-title":"Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial","volume":"47","author":"Bosch","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1053\/j.gastro.2004.07.015","article-title":"Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0105","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2014.03.035","article-title":"Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials","volume":"61","author":"Bendtsen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0036-1597770","article-title":"Hemostasis in Acute and Chronic Liver Disease","volume":"37","author":"Tripodi","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0115","doi-asserted-by":"crossref","first-page":"442-52.e1","DOI":"10.1053\/j.gastro.2013.10.012","article-title":"Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy","volume":"146","author":"Afdhal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.13305","article-title":"Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia","author":"Ishikawa","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jvir.2012.02.012","volume":"23","author":"Patel","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0130","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/trf.12431","article-title":"Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy","volume":"54","author":"Levy","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2015.10.019","article-title":"Management of the critically ill patient with cirrhosis: a multidisciplinary perspective","volume":"64","author":"Nadim","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0140","doi-asserted-by":"crossref","first-page":"830","DOI":"10.5604\/01.3001.0012.0775","article-title":"Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients","volume":"17","author":"Giannini","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0145","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/liv.13728","article-title":"Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients","volume":"38","author":"Bianchini","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.27783","article-title":"Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study","volume":"62","author":"Cerini","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0155","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1111\/jth.14265","article-title":"The utility of viscoelastic methods in the prevention and treatment of bleeding and hospital-associated venous thromboembolism in perioperative care: guidance from the SSC of the ISTH","volume":"16","author":"Thomas","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0160","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5500\/wjt.v6.i3.583","article-title":"Thromboelastographic reference ranges for a cirrhotic patient population undergoing liver transplantation","volume":"6","author":"De Pietri","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0165","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/jth.14447","article-title":"Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: a systematic review and analysis","volume":"17","author":"Dias","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-13-1","article-title":"A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis","volume":"13","author":"Lanc\u00e9","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0175","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0049-3848(11)70007-X","article-title":"Thrombin generation tests","volume":"127","author":"Castoldi","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin Generation Assay and Its Application in the Clinical Laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0185","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.dsx.2016.12.033","article-title":"Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis","volume":"11","author":"Mahfood Haddad","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0190","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005307","article-title":"Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"Kuo","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0195","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.18632\/oncotarget.22755","article-title":"Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: aa meta-analysis","volume":"9","author":"Hu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"Sogaard","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0205","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s10620-011-1582-5","article-title":"Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis","volume":"56","author":"Ali","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0210","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1378\/chest.09-2177","article-title":"Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease","volume":"137","author":"Dabbagh","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis","volume":"117","author":"Ambrosino","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41424-018-0002-y","article-title":"Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis","volume":"9","author":"Stine","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0225","doi-asserted-by":"crossref","first-page":"514","DOI":"10.5604\/01.3001.0010.0279","article-title":"Hepatitis C Virus Infection and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis","volume":"16","author":"Wijarnpreecha","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0230","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/jth.14255","article-title":"Venous thromboembolism in patients with liver diseases","volume":"16","author":"Barba","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0235","first-page":"1238","article-title":"Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension","volume":"21","author":"Wanless","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0240","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/hep.510270224","article-title":"Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules","volume":"27","author":"Tanaka","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0245","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0250","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","article-title":"Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation","volume":"54","author":"Francoz","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0255","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0260","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ajg.2012.452","article-title":"De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes","volume":"108","author":"Maruyama","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0265","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1148\/radiol.12112236","article-title":"Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis","volume":"265","author":"Luca","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0270","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/hep.1840160515","article-title":"The incidence of portal vein thrombosis at liver transplantation","volume":"16","author":"Nonami","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0275","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2004.01.001","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0280","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0285","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MEG.0000000000000325","article-title":"De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system","volume":"27","author":"Abdel-Razik","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0290","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/liv.13500","article-title":"Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study","volume":"38","author":"Stine","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0295","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/lt.24134","article-title":"Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis","volume":"21","author":"Stine","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0300","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11239-014-1124-z","article-title":"Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis","volume":"40","author":"Saugel","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0305","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MAJ.0b013e31826485fc","article-title":"Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis","volume":"346","author":"Qi","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0310","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.thromres.2014.05.012","article-title":"Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event","volume":"134","author":"Chaireti","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0315","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/MEG.0000000000000352","article-title":"Procoagulant imbalance aggravated with falling liver function reserve, but not associated with the presence of portal vein thrombosis in cirrhosis","volume":"27","author":"Tang","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0320","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1111\/hepr.12520","article-title":"Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis","volume":"46","author":"Kalambokis","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0325","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.blre.2014.10.002","article-title":"Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?","volume":"29","author":"Hugenholtz","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0330","doi-asserted-by":"crossref","first-page":"506136","DOI":"10.1155\/2015\/506136","article-title":"Splanchnic Vein Thrombosis: Etiology, Diagnosis, and Treatment","volume":"2015","author":"Qi","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0335","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/lt.24387","article-title":"Nontumoral portal vein thrombosis in patients awaiting liver transplantation","volume":"22","author":"Chen","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0340","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/SLA.0000000000000252","article-title":"When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases","volume":"259","author":"Hibi","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0345","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.gastro.2015.07.028","article-title":"Lack of Survival Benefit Following Liver Transplantation With MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice","volume":"149","author":"Ghabril","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0350","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0355","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s10620-012-2548-y","article-title":"Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation","volume":"58","author":"Werner","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0360","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0365","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0370","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/MEG.0000000000000351","article-title":"Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B","volume":"27","author":"Cui","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0375","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0380","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs. traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0385","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0390","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0395","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0400","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: Vascular diseases of the liver","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0405","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/j.2040-4603.2013.tb00529.x","article-title":"Hepatic stellate cells and liver fibrosis","volume":"3","author":"Puche","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11901-018-0406-x","article-title":"The Role of Anticoagulation in Treating Portal Hypertension","volume":"17","author":"Turco","year":"2018","journal-title":"Curr Hepatology Rep"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0415","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0420","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0425","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3748\/wjg.v9.i7.1611","article-title":"Effects of heparin on liver fibrosis in patients with chronic hepatitis B","volume":"9","author":"Shi","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0430","first-page":"408","article-title":"Indigenous and imported low molecular weight heparin in the treatment of chronic hepatitis B and cirrhosis with hepatitis B virus: a prospective randomized controlled clinical study","volume":"19","author":"Huang","year":"2007","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0435","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(15)30165-3","article-title":"Warfarin anticoagulation for liver fibrosis in patients transplanted for Hepatitis C (WAFT-C): Results at one year","volume":"62","author":"Dhar","year":"2015","journal-title":"J Hep"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0440","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1538-7836.2012.04824.x","article-title":"Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis","volume":"10","author":"Senzolo","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0445","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.12593","article-title":"Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis","volume":"163","author":"Potze","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0450","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0455","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0460","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood-2007-11-123711","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based","volume":"111","author":"Levi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0465","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/CIRCOUTCOMES.113.000817","article-title":"Stratifying the risks of oral anticoagulation in patients with liver disease","volume":"7","author":"Efird","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0470","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral Anticoagulation in Patients With Liver Disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0475","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/liv.12211","article-title":"Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhotic patients is not associated with high rates of gastrointestinal bleeding","volume":"34","author":"Intagliata","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0480","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ejh.13045","article-title":"Safety of direct oral anticoagulants vs. warfarin in patients with chronic liver disease and atrial fibrillation","volume":"100","author":"Goriacko","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0485","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0490","author":"European Medicines Agency"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0495","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-155-9-201111010-00011","article-title":"Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians","volume":"155","author":"Qaseem","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0500","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(08)60202-0","article-title":"Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study","volume":"371","author":"Cohen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-9-1","article-title":"The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients","volume":"9","author":"Aldawood","year":"2011","journal-title":"Thromb J"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0510","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/imj.13766","article-title":"Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients","volume":"48","author":"Yang","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0515","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/phar.1218","article-title":"Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease","volume":"33","author":"Barclay","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0520","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","article-title":"Low-molecular-weight heparin in patients with advanced cirrhosis","volume":"31","author":"Bechmann","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0525","first-page":"1261A","article-title":"Clinical outcome of portal vein thrombosis (PVT) in cirrhotic patients: observe or treat?","volume":"54","author":"Caracciolo","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0530","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3350\/cmh.2014.20.4.384","article-title":"Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis","volume":"20","author":"Chung","year":"2014","journal-title":"Clin Mole Hepatol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2014.01.093","article-title":"Liver transplantation in cirrhotic patients with portal vein thrombosis: a single centre experience","volume":"46","author":"Risso","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0540","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1148\/radiol.2015150369","article-title":"Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial","volume":"279","author":"Wang","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0545","article-title":"Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0550","article-title":"Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis","author":"Pettinari","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0555","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.08.011","article-title":"Direct oral anticoagulants in patients with liver cirrhosis: A systematic review","volume":"170","author":"Hoolwerf","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jhepr.2019.02.006_bb0560","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/MEG.0000000000001219","article-title":"The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis","volume":"30","author":"Valentin","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919300059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919300059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:33Z","timestamp":1762899813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555919300059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2589555919300059"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.02.006","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in the cirrhotic patient","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}]}}